TITLE

Recent progress on normal and malignant pancreatic stem! progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer

AUTHOR(S)
Mimeault, M.; Batra, S. K.
PUB. DATE
October 2008
SOURCE
Gut;Oct2008, Vol. 57 Issue 10, p1456
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recent progress on pancreatic stem/progenitor cell research has revealed that the putative multipotent pancreatic stem/progenitor cells and/or more committed beta cell precursors may persist in the pancreatic gland in adult life. The presence of immature pancreatic cells with stem cell-like properties offers the possibility of stimulating their in vivo expansion and differentiation or to use their ex vivo expanded progenies for beta cell replacement-based therapies for type 1 or 2 diabetes mellitus in humans. In addition, the transplantation of either insulin-producing beta cells derived from embryonic, fetal and other tissue-resident adult stem/progenitor cells or genetically modified adult stem/progenitor cells may also constitute alternative promising therapies for treating diabetic patients. The genetic and/or epigenetic alterations in putative pancreatic adult stem/progenitor cells and/or their early progenies may, however, contribute to their acquisition of a dysfunctional behaviour as well as their malignant transformation into pancreatic cancer stem/progenitor cells. More particularly, the activation of distinct tumorigenic signalling cascades, including the hedgehog, epidermal growth factor-epidermal growth factor receptor IEGF-EGFR) system, wingless ligand (Wnt)β-catenin and/or stromal cell-derived factor-1 (SDF-1 )-CXC chemokine receptor 4 (CXCR4) pathways may play a major role in the sustained growth, survival, metastasis and/or drug resistance of pancreatic cancer stem/progenitor cells and their further differentiated progenies. The combination of drugs that target the oncogenic elements in pancreatic cancer stem/progenitor cells and their microenvironment, with the conventional chemotherapeutic regimens, could represent promising therapeutic strategies. These novel targeted therapies should lead to the development of more effective treatments of locally advanced and metastatic pancreatic cancers, which remain incurable with current therapies.
ACCESSION #
34640832

 

Related Articles

  • P-0038PANCREATIC STELLATE CELLS AGGRAVATE PAIN IN PANCREATIC CANCER THROUGH HEDGEHOG SIGNALING PATHWAY. Han, Liang; Li, Wei; Duan, Wanxing; Yu, Shuo; Chen, Chao; Zhang, Lun; Xu, Qinhong; Lei, Jianjun; Ma, Qingyong // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv47 

    No abstract available.

  • Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. Vaz, A P; Ponnusamy, M P; Rachagani, S; Dey, P; Ganti, A K; Batra, S K // British Journal of Cancer;7/29/2014, Vol. 111 Issue 3, p486 

    Background:Cancer stem cells (CSCs) contribute towards disease aggressiveness and drug resistance. Specific identification of CSC maintenance genes and targeting can improve the efficiency of currently available treatment modalities. Pancreatic differentiation 2 (PD2) has a major role in the...

  • Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Miyagawa, Katsutosh; Kondo, Tatsuya; Goto, Rieko; Matsuyama, Rina; Ono, Kaoru; Kitano, Sayaka; Kawasaki, Shuji; Igata, Motoyuki; Kawashima, Junji; Matsumura, Takeshi; Motoshima, Hiroyuki; Araki, Eiichi // Cardiovascular Diabetology;2013, Vol. 12 Issue 1, p1 

    Background Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate incretin hormones and exert anti-diabetic effects in type 2 diabetes mellitus. Treatment with angiotensin II type 1 receptor blockers (ARB) is a proven successful intervention for hypertension with type 2 diabetes. The present study...

  • Disruption of a Gene May Prevent Type 1 Diabetes, University of Virginia Researchers Find.  // Ascribe Newswire: Medicine;5/13/2004, p64 

    Disrupting a gene called Stat-4 suppresses the activation of white blood cells involved in the development of type 1 diabetes, say researchers from the University of Virginia Health System in the May issue of "The Journal of Autoimmunity." Type 1 diabetes occurs when the body's immune system...

  • TNF-Related Apoptosis-Inducing Ligand Death Pathway-Mediated Human Beta-Cell Destruction D. Ou et al.: A novel cytokine pathway-induced beta-cell destruction. Ou, D.; Metzger, D.; Wang, X.; Huang, J.; Pozzilli, P.; Tingle, A. // Diabetologia;Dec2002, Vol. 45 Issue 12, p1678 

    Aims/hypothesis. The aim of this study is to investigate whether apoptosis in human beta cells can be related to the induction of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway. Methods. We examined the expression of TRAIL and TRAIL receptors in two human pancreatic...

  • Imbalanced expression of Tif1y inhibits pancreatic ductal epithelial cell growth. Ligr, Martin; Xinyu Wu; Daniels, Garrett; Zhang, David; Huamin Wang; Hajdu, Cristina; Jinhua Wang; Pan, Ruimin; Zhiheng Pei; Lanjing Zhang; Melis, Marcovalerio; Pincus, Matthew R.; Saunders, John K.; Peng Lee; Ruliang Xu // American Journal of Cancer Research;2014, Vol. 4 Issue 3, p196 

    Transcriptional intermediary factor 1 gamma (Tif1y) (Ectodermin/PTC7/RFG7/TRIM33) is a transcriptional cofactor with an important role in the regulation of the TGFβ pathway. It has been suggested that it competes with Smad2/Smad3 for binding to Smad4, or alternatively that it may target Smad4...

  • First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Saif, Muhammad; Li, Jia; Lamb, Lynne; Kaley, Kristin; Elligers, Kyle; Jiang, Zaoli; Bussom, Scott; Liu, Shwu-Huey; Cheng, Yung-Chi // Cancer Chemotherapy & Pharmacology;Feb2014, Vol. 73 Issue 2, p373 

    Background: Preclinical studies showed a Chinese botanical formula, PHY906, has synergistic anti-tumor activity with capecitabine. Our phase I study determined maximal tolerated dose of capecitabine 1,500 mg/m BID day 1-7 and PHY906 800 mg BID day 1-4 every 2 weeks. We conducted this phase II...

  • The potential of panHER inhibition in cancer. Xiaochun Wang; Batty, Kathleen M.; Crowe, Philip J.; Jia-Lin Yang; Goldstein, David // Frontiers in Oncology;Jan2015, Vol. 5, p1 

    Purpose: Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to upregulation of the three vital signaling pathways: mitogen activated protein kinase, phosphoinositide 3-kinase/AKT, and Janus kinase/signal transducer and activator of transcription pathways. Blocking HER1/EGFR has...

  • Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer. Nurwidya, Fariz; Murakami, Akiko; Takahashi, Fumiyuki; Takahashi, Kazuhisa // Cancer Biology & Medicine;2012, Vol. 9 Issue 1, p18 

    One of the most important pathways in non-small cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR) pathway. This pathway affects several crucial processes in tumor development and progression, including tumor cell proliferation, apoptosis regulation, angiogenesis, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics